H.C. Wainwright lowered the firm’s price target on Lexeo Therapeutics (LXEO) to $15 from $23 and keeps a Buy rating on the shares. The firm says that while Rocket Pharmaceuticals’ (RCKT) adeno-associated viral vector-based gene therapy RP-A601 adds validation for Lexeo’s LX2020, RP-A601 faces safety challenges that put LX2020 ahead. While efficacy biomarkers are positive, RP-A601 appears to have meaningful safety issues, the analyst tells investors in a research note. H.C. Wainwright cut Lexeo’s price target after accounting for an increase in potentially dilutive securities outstanding.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LXEO:
- Lexeo Therapeutics: Strategic Focus and Promising Pipeline Drive Buy Rating
- Lexeo Therapeutics Reports Increased Losses Amid R&D Expansion
- Lexeo Therapeutics price target lowered to $20 from $22 at Chardan
- Lexeo Therapeutics reports Q1 EPS (99c), consensus (77c)
- Controversial doctor Vinay Prasad named CBER director, STAT reports
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue